CD-7 Immunohistochemistry at Test Zone Diagnostic Center

CD-7 Immunohistochemistry at Test Zone Diagnostic Center

CD-7 Immunohistochemistry at Test Zone Diagnostic Center is a highly specialized, state-of-the-art pathology investigation utilized for the precise identification and characterization of cellular lineages in complex hematological and lymphoid disorders. The Cluster of Differentiation 7 (CD-7) is a 40 kDa single-chain transmembrane glycoprotein that belongs to the immunoglobulin superfamily. It is one of the earliest antigenic markers expressed during T-cell ontogeny, appearing on pre-thymic T-cell precursors before the rearrangement of T-cell receptor genes. Because of its early expression and persistence throughout T-cell maturation, CD-7 serves as an indispensable marker in diagnostic pathology. Immunohistochemistry (IHC) is a laboratory technique that combines anatomical, immunological, and biochemical techniques to image specific tissue antigens. By utilizing highly specific monoclonal antibodies directed against the CD-7 antigen, pathologists at Test Zone Diagnostic Center can visualize the presence, distribution, and intensity of this protein within tissue sections under a light microscope. This diagnostic tool is critical for distinguishing between reactive lymphoid proliferations and malignant lymphomas, classifying acute leukemias, and evaluating cutaneous T-cell lymphoproliferative disorders. The clinical value of this test lies in its ability to provide objective, molecular-level evidence that complements traditional morphological examination, enabling oncologists to formulate highly targeted, personalized treatment strategies for patients in Sargodha and surrounding regions.

Clinical Procedure: What to Expect

Patient Preparation

Because CD-7 Immunohistochemistry is an advanced laboratory test performed on tissue specimens that have already been collected, there is no direct preparation required for the staining process itself. However, the preparation for the primary biopsy procedure used to obtain the tissue specimen is of paramount importance. Patients undergoing a lymph node biopsy, bone marrow aspiration, or skin biopsy must adhere to the following clinical guidelines: First, inform your referring physician and the clinical team at Test Zone Diagnostic Center about all current medications, especially anticoagulants, antiplatelet agents, or non-steroidal anti-inflammatory drugs, as these may need to be temporarily discontinued to minimize bleeding risks. Second, if the biopsy is to be performed under conscious sedation or general anesthesia, you may be required to fast for six to eight hours prior to the procedure. Third, ensure that you bring all previous medical records, including complete blood counts, imaging scans, and prior histopathology reports, to assist the pathologist in clinical correlation. Finally, wear loose, comfortable clothing on the day of the biopsy to facilitate easy access to the biopsy site, and arrange for a family member or guardian to accompany you home after the procedure.

During the Procedure

The diagnostic journey of CD-7 Immunohistochemistry involves several meticulous phases, beginning with the primary specimen collection. Depending on the clinical indication, a qualified specialist will perform a biopsy to obtain a representative tissue sample, such as an excisional lymph node biopsy, a core needle biopsy of a solid mass, a trephine bone marrow biopsy, or a punch biopsy of the skin. Once the specimen is obtained, it is immediately placed in a container filled with 10% neutral buffered formalin to prevent autolysis and preserve cellular morphology. At the histopathology laboratory of Test Zone Diagnostic Center, the tissue undergoes systematic processing, which includes dehydration, clearing, and embedding in paraffin wax to create a solid block. Ultra-thin sections, measuring approximately four micrometers, are cut from this paraffin block using a precision microtome and mounted onto glass slides. The slides then undergo deparaffinization and rehydration, followed by heat-induced epitope retrieval (HIER) to unmask the CD-7 antigen sites. The tissue sections are incubated with high-affinity primary monoclonal antibodies specific to CD-7. After washing away unbound antibodies, a polymer-based secondary detection system conjugated with horseradish peroxidase is applied, followed by the addition of a chromogen substrate, typically 3,3′-Diaminobenzidine (DAB). This reaction produces a highly visible, insoluble brown precipitate at the site of CD-7 antigen expression. Finally, the slides are counterstained with hematoxylin, dehydrated, cleared, coverslipped, and delivered to a Consultant Pathologist for detailed microscopic evaluation.

When is a CD-7 Immunohistochemistry at Test Zone Diagnostic Center Performed?

Evaluation of Acute Lymphoblastic Leukemia

Physicians frequently request CD-7 Immunohistochemistry when evaluating patients suspected of having acute lymphoblastic leukemia (ALL). CD-7 is the most sensitive marker for T-cell lineage acute lymphoblastic leukemia (T-ALL), being expressed in virtually all cases. It is particularly valuable in identifying early T-cell precursor (ETP) leukemia, a high-risk subtype of T-ALL that exhibits a distinct immunophenotypic profile. By demonstrating strong, diffuse membranous CD-7 expression on immature blast cells, the pathologist can confidently differentiate T-ALL from B-cell acute lymphoblastic leukemia (B-ALL) and other poorly differentiated neoplasms, which is vital because the therapeutic protocols for these malignancies differ significantly.

Diagnosis of Cutaneous T-Cell Lymphomas

Cutaneous T-cell lymphomas, such as Mycosis Fungoides and Sézary syndrome, present a significant diagnostic challenge due to their clinical and histological similarity to benign inflammatory dermatoses. One of the hallmark immunophenotypic features of malignant T-cells in Mycosis Fungoides is the aberrant loss of normal pan-T-cell antigens, with CD-7 being the most frequently lost marker. Pathologists perform CD-7 IHC on skin punch biopsies to assess the proportion of T-lymphocytes that lack CD-7 expression. A finding where a significant majority of the intraepidermal and dermal T-cell infiltrate is CD-7 negative, while retaining other T-cell markers like CD3, strongly supports a diagnosis of cutaneous T-cell lymphoma over a reactive inflammatory condition.

Characterization of Peripheral T-Cell Lymphomas

Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of aggressive nodal and extranodal malignancies. Because mature T-cell neoplasms often exhibit variable antigen loss, a comprehensive IHC panel including CD-7 is essential for accurate characterization. The loss of CD-7 expression in a clonal lymphoid population within a lymph node or extranodal site is a highly reliable indicator of T-cell neoplasia. This helps the clinical team at Test Zone Diagnostic Center differentiate aggressive PTCL from reactive, atypical T-cell hyperplasia, which can occur in response to viral infections or autoimmune diseases.

Assessment of Acute Myeloid Leukemia

Although CD-7 is primarily a T-cell associated marker, it is aberrantly expressed in approximately 20% to 30% of cases of Acute Myeloid Leukemia (AML), particularly those with minimal differentiation (FAB M0) or erythroid/megakaryocytic differentiation. The detection of aberrant CD-7 expression in AML is clinically significant as it often correlates with specific genetic alterations, such as RUNX1 mutations, and can be associated with an adverse prognosis. Furthermore, identifying CD-7 expression on myeloid blasts at the time of initial diagnosis provides a unique immunophenotypic fingerprint that can be used as a marker for tracking minimal residual disease (MRD) following chemotherapy.

Investigation of Unexplained Lymphadenopathy

Persistent, unexplained lymphadenopathy requires a thorough histopathological investigation to rule out malignancy. When a lymph node biopsy reveals an atypical lymphoid infiltrate, CD-7 Immunohistochemistry is performed alongside other lymphoid markers to map the architectural distribution of T-cells. In reactive lymph nodes, CD-7 positive T-cells are localized predominantly within the paracortical zones in a well-organized pattern. A disruption of this normal architectural pattern, characterized by sheets of atypical CD-7 positive cells or, conversely, a complete absence of CD-7 expression within an atypical lymphoid expansion, alerts the pathologist to the presence of a lymphoproliferative disorder.

What Does a CD-7 Immunohistochemistry Detect?

CD-7 Immunohistochemistry is designed to detect the presence, localization, intensity, and distribution of the CD-7 glycoprotein on the cell membrane of lymphoid and myeloid cells. Specifically, this advanced pathological assay detects and evaluates: the presence of CD-7 antigen on precursor T-cells; the expression of CD-7 on mature peripheral T-lymphocytes; CD-7 expression on Natural Killer (NK) cells; the aberrant loss of CD-7 in cutaneous T-cell lymphoma (Mycosis Fungoides); the aberrant expression of CD-7 in Acute Myeloid Leukemia (AML) blasts; strong, diffuse membranous staining in T-cell Acute Lymphoblastic Leukemia (T-ALL); the proportion of CD-7 positive lymphoid cells in reactive lymph nodes; the co-expression of CD-7 with other T-cell markers such as CD3, CD2, and CD5; the lack of CD-7 expression in B-cell lymphoproliferative disorders; the distribution pattern of CD-7 positive cells within the paracortex of lymph nodes; the preservation of CD-7 expression in benign inflammatory dermatoses; CD-7 positivity in early hematopoietic progenitor cells in bone marrow; the intensity of CD-7 staining categorized as weak, moderate, or strong; the percentage of tumor cells showing membranous CD-7 immunoreactivity; the presence of CD-7 positive intraepidermal lymphocytes; CD-7 expression in hepatosplenic T-cell lymphoma; CD-7 expression in anaplastic large cell lymphoma; CD-7 positivity in normal thymocytes; the infiltration of CD-7 positive cells in non-lymphoid tissues; and minimal residual disease tracking in CD-7 positive leukemias. By analyzing these specific parameters, the pathologist can formulate a highly precise diagnostic report.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that a timely and accurate diagnosis is critical for effective clinical decision-making, particularly in oncological cases. The turnaround time for CD-7 Immunohistochemistry typically ranges from three to five working days. This timeframe is necessary to ensure the highest standards of quality control, including precise tissue processing, optimal antigen retrieval, overnight antibody incubation, and detailed microscopic review by our Consultant Pathologists. Once the diagnostic report is finalized, patients and referring physicians can access it conveniently online through the secure Test Zone Diagnostic Center web portal. Additionally, physical copies of the report, complete with high-resolution photomicrographs if requested, can be collected directly from our main diagnostic facility in Sargodha, Punjab, Pakistan.

CD-7 Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
T-lymphocytes (Precursors)	Strong, diffuse membranous CD7 positivity	Absence or weak expression in early T-cell precursor neoplasms
Mature Peripheral T-cells	Membranous CD7 expression in over 90% of cells	Significant loss of expression (less than 50% positive) in cutaneous T-cell lymphoma
Lymph Node Paracortex	Normal, organized distribution of CD7-positive T-cells	Disruption of architecture with sheets of CD7-positive atypical blasts
Bone Marrow Myeloid Precursors	Negative for CD7 expression	Aberrant CD7 expression in myeloblasts, suggestive of AML
Natural Killer (NK) Cells	Positive CD7 expression	Loss or aberrant overexpression in NK/T-cell lymphomas
Epidermal Infiltrates (Skin Biopsy)	Rare, scattered CD7-positive reactive T-cells	Intraepidermal microabscesses of CD7-negative atypical T-cells
B-lymphocytes / Follicles	Negative for CD7 expression	Aberrant CD7 expression in rare biphenotypic acute leukemias

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for CD-7 Immunohistochemistry?

• Experienced healthcare professionals including highly qualified Consultant Pathologists and skilled histotechnologists.
• Patient-focused care that ensures comfort, dignity, and clear communication throughout the diagnostic process.
• Quality diagnostic services adhering to international standards of laboratory practice and quality control.
• Professional reporting featuring comprehensive microscopic descriptions and clinical correlation.
• Modern diagnostic approach utilizing advanced automated immunohistochemistry staining platforms.
• Comfortable environment designed to make sample collection and biopsy procedures as stress-free as possible.
• Convenient location in Sargodha, Punjab, Pakistan, providing easy access for patients across the region.
• Commitment to accurate diagnosis to ensure timely and effective oncological and hematological treatment planning.